Gilead Sciences Goodwill

Gilead Sciences posts a goodwill of $8.3B as of June 2026. That compares with $8.3B in the prior-year period — up 0.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Gilead Sciences's goodwill was $8.3B. The latest reading is $8.3B — essentially flat versus a year earlier (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Goodwill is one piece of Gilead Sciences's financial statement story. At $8.3B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for GILD's goodwill usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Gilead Sciences's other metric pages and overview cover the third.

Judging Gilead Sciences against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in goodwill easier to interpret. Start with $8.3B here, then scan peer and history charts to see if the gap is persistent.